Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

It’s All About the Weed for Aphria Stock

While Aphria’s growth capacity expansion is big news, a more critical catalyst for Aphria stock could be its medicinal marijuana brand.

Education Can Go a Long Way for Aurora Cannabis Stock

Wall Street has penalized Aurora Cannabis stock for the underlying company’s aggressive expansionary strategy. However, that expansion may have been necessary to bring to volume ACB’s premium-quality medicinal cannabis products.

3 Key Issues Advanced Micro Devices Stock Faces

Although AMD stock has been a top performer over the past few years, the longer-term case is starting to look dull for several different reasons. Here's what Advanced Micro investors should know.

Sentiment and a Reinvigorated Sector Make ATVI Stock a Smart Buy

Due to the resounding, record-breaking debut of Activision Blizzard’s Modern Warfare, it appears that gamers once again desire gritty realism in their shooter games. If so, that’s wonderful news for ATVI stock over the long haul.

The Good, Bad, and Ugly for Biogen Stock

With news that Biogen’s Alzheimer’s drug was allowed to reapply for possible FDA approval, Biogen stock skyrocketed. However, investors will want to carefully consider all angles before jumping onboard.